Homes in Sheboygan County sold for lower prices in February: See how much here
The median home sold for $242,000, an analysis of data from Realtor.com shows. That means February, the most recent month for which figures are available, was down 2.2% from January.
Compared to February 2024, the median home sales price was down 4.2% compared to $252,500.
Realtor.com sources sales data from real estate deeds, resulting in a few months' delay in the data. The statistics don't include homes currently listed for sale and aren't directly comparable to listings data.
Information on your local housing market, along with other useful community data, is available at data.jsonline.com.
Here is a breakdown on median sale prices:
Looking only at single-family homes, the $241,000 median selling price in Sheboygan County was down 3.6% in February from $250,000 the month prior. Since February 2024, the sales price of single-family homes was down 9% from a median of $264,950. Two single family homes sold for $1 million or more during the month, compared to one recorded transactions of at least $1 million in February 2024.
Condominiums and townhomes increased by 57.2% in sales price during February to a median of $286,000 from $181,950 in January. Compared to February 2024, the sales price of condominiums and townhomes was up 40.9% from $202,950. No condominiums or townhomes sold for $1 million or more during February.
In February, the number of recorded sales in Sheboygan County rose by 1.2% since February 2024 — from 84 to 85. All residential home sales totaled $26.7 million.
Across Wisconsin, homes sold at a median of $270,550 during February, up 1.3% from $266,979 in January. There were 4,203 recorded sales across the state during February, up 1% from 4,163 recorded sales in February 2024.
Here's a breakdown for the full state:
The total value of recorded residential home sales in Wisconsin decreased by 12.3% from $1.6 billion in January to $1.4 billion this February.
Out of all residential home sales in Wisconsin, 2.66% of homes sold for at least $1 million in February, up from 2.4% in February 2024.
Sales prices of single-family homes across Wisconsin increased by 1.4% from a median of $270,000 in January to $273,857 in February. Since February 2024, the sales price of single-family homes across the state was up 9.6% from $249,994.
Across the state, the sales price of condominiums and townhomes rose 4.6% from a median of $252,500 in January to $264,000 during February. The median sales price of condominiums and townhomes is up 6.8% from the median of $247,300 in February 2024.
The median home sales price used in this report represents the midway point of all the houses or units listed over the given period of time. The median offers a more accurate view of what's happening in a market than the average sales price, which would mean taking the sum of all sales prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high sale.
The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Realtor.com. Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us.
This article originally appeared on Sheboygan Press: Homes in Sheboygan County Wisconsin prices
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
US Fed independence under threat, say economists, but no one expects a July rate cut- Reuters poll
By Indradip Ghosh BENGALURU -The U.S. Federal Reserve's independence is under threat from mounting political interference, according to a clear majority of economists polled by Reuters, although no one expects a July interest rate cut despite a recent divergence in views among policymakers. President Donald Trump has made it almost a daily routine to personally attack Fed Chair Jerome Powell over the central bank's stance of holding rates due to tariff-related risks of higher inflation. A recent jump in inflation suggests businesses are now passing some of the tariffs onto consumers. Most Federal Market Open Committee members favor holding rates steady, but a few, including Governor Chris Waller and Trump appointee Fed Vice Chair for Supervision Michelle Bowman, have recently advocated a reduction as soon as July 30. Powell's term is set to expire in May 2026. Waller last week said he would accept the job as the bank's head if he was offered it by Trump. An over 70% majority of economists in the July 17-23 Reuters poll who answered an additional question, 36 of 50, said they were worried about the Fed's independence from political influence, including 10 who said they were very concerned. The remaining 14 said they were not. "I am more worried about the Fed's independence than I was a few months ago, and the main reason for that is the recent behaviour of Governors Bowman and Waller. It's very notable they are diverging from the consensus," said Philip Marey, senior U.S. strategist at Rabobank. "This year is still Powell's Fed. The current Fed is very cautious and wants to wait for the data and go only when they're sure ... It is kind of a policy paralysis at the moment and I don't think that will change as long as Powell has some grip on the FOMC," he added. All 105 economists said the Fed, which last cut its key interest rate to 4.25%-4.50% in December, will hold rates again at the conclusion of its July 29-30 meeting. Most respondents maintained their rate outlook or expected fewer reductions compared with a poll taken last month. A slight 53% majority of economists, 56 of 105, forecast a cut in September, in line with market pricing. But with less than half the year remaining, a clear consensus on where rates would be by end-2025 remains elusive. Economists are waiting for clarity on trade policies as a deadline for Trump's so-called "reciprocal" tariffs first announced in April approaches. That deadline of August 1 is itself an extension from a previous July 9 deadline. "Tariffs could affect things both in terms of higher inflation (and) it could slow the economy. The Fed doesn't know exactly what that mix is going to be and that's reason enough to wait," said Jonathan Millar, senior U.S. economist at Barclays. Just under two-thirds of forecasters expect one or two rate cuts this year, with nearly a fifth expecting no cuts at all. Interest rate futures are pricing in two reductions. The Fed will cut twice next year, poll medians showed. "We've had a very substantial easing of policy over the last few months just from the fact the dollar has weakened and improvements in equity markets. It's not as if things are really screaming out for a rate cut," Millar said. Inflation forecasts were broadly unchanged from last month, with economists forecasting it will average above the Fed's 2% target through at least 2027. The recent passage of Trump's signature spending bill, expected to add $3.4 trillion to an already enormous $36.2 trillion debt pile, poses a further risk of reigniting price pressures. The economy, which contracted 0.5% last quarter, is forecast to grow just 1.5% this year, a sharp slowdown from 2.8% in 2024. Next year, it was expected to expand 1.6%, a view that has remained steady since May. (Other stories from the Reuters global economic poll) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test
Company Launches New Website, Scales Test Access Alongside Mayo Clinic, & Looks to Expand International Presence SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, has announced several strategic growth initiatives to broaden access to its SAAmplify-ɑSYN test. These initiatives include a comprehensive website refresh, expanded test availability via Mayo Clinic's network of hospitals and clinical sites, and ongoing preparations for international expansion. As part of its continuing growth and commitment to advancing early and accurate diagnosis, Amprion will showcase its latest developments and momentum at the Alzheimer's Association International Conference (AAIC), July 27-31, 2025, in Toronto, Canada. Attendees can connect with the Amprion team at booth #616. Following its recent collaboration with Mayo Clinic Laboratories, Amprion launched a newly redesigned website to meet the growing demand for its SAAmplify-ɑSYN test, which aids in the diagnosis of synucleinopathies. The breakthrough test can detect the presence of aggregates of alpha-synuclein protein, the underlying pathology of Parkinson's disease (PD), Lewy body dementia (LBD), multiple system atrophy (MSA), and Alzheimer's disease with Lewy bodies (AD + DLB), in cerebrospinal fluid. Launched earlier this month, the updated website is designed to provide patients, clinicians, and industry leaders with streamlined access to Amprion's latest research, information, and more. "As awareness and demand for our SAAmplify-ɑSYN test grow, we're working to ensure clinicians, researchers, and patients have better access to the tools and information they need," said Dr. Russ Lebovitz, CEO and co-founder of Amprion. "Our refreshed website and expanding partnerships are steps toward that goal, and we look forward to connecting with the global neuroscience community at AAIC." Due to this surge in awareness, Amprion is actively exploring international expansion opportunities, with plans to bring its test to European and global markets. Initial announcements regarding country-specific launch strategies are expected in Q4 2025. For more information or to schedule a meeting with Amprion at AAIC 2025, please visit About SAAmplify-ɑSYN (formerly SYNTap®) Amprion's SAAmplify-ɑSYN test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with Lewy body co-pathology. The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. The test became commercially available in the US in 2021. About Amprion Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion's intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease, Lewy body dementia, and Alzheimer's disease with Lewy body co-pathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at or find us on LinkedIn. View source version on Contacts Media Contacts Liz RobinsonCG Lifelrobinson@ Karen SharmaCG Lifeksharma@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide
-- Boston Scientific (NYSE:BSX) posted second-quarter results that topped expectations, driven by strong organic growth and solid performance across key regions. Adjusted EPS came in at $0.75, beating the $0.73 consensus. Revenue rose to $5.06 billion, up 22.8% year-over-year, exceeding the $4.89 billion forecast. On an organic basis, sales increased 17.4% year-over-year. "This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth," said Mike Mahoney, chairman and CEO of Boston Scientific. The company saw strong double-digit growth in the U.S. and Asia-Pacific of 30.7% and 18%, respectively, while EMEA and Latin America posted more modest gains. Emerging markets also contributed with healthy growth. For the third quarter, it guided to EPS of $0.70 to $0.72, compared to expectations of $0.70. Looking further ahead, Boston Scientific expects full-year 2025 EPS in the range of $2.95 to $2.99, above the $2.92 consensus. Related articles Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia After soaring 149%, this stock is back in our AI's favor - & already +25% in July
